INS and diabetes mellitus: For example, glucagon-like peptide 1 (GLP1), a target therapeutic peptide in the treatment of diabetes, binds to the GLP1 receptor on the surface of islet cells and then transmits signals to the nucleus via the insulin signaling pathway to activate insulin secretion and inhibit glucagon release [10].